135 related articles for article (PubMed ID: 1455396)
21. Thrombogenicity of factor IX complex: in vivo investigation.
Aronson DL; Menache D
Dev Biol Stand; 1987; 67():149-55. PubMed ID: 3609475
[TBL] [Abstract][Full Text] [Related]
22. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate.
Mannucci PM; Bauer KA; Gringeri A; Barzegar S; Santagostino E; Tradati FC; Rosenberg RD
Br J Haematol; 1991 Dec; 79(4):606-11. PubMed ID: 1772782
[TBL] [Abstract][Full Text] [Related]
23. [Thrombin formation in factor IX concentrates and FEIBA (factor eight inhibitor bypassing activity) (proceedings)].
Hofmann V; Ermanni M; Straub PW
Schweiz Med Wochenschr; 1978 Oct; 108(41):1600. PubMed ID: 694497
[TBL] [Abstract][Full Text] [Related]
24. Inhibitory effect of hirudin on thrombosis induced by prothrombin complex concentrates.
Klöcking HP; Schulze-Riewald H; Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):106-9. PubMed ID: 2459002
[TBL] [Abstract][Full Text] [Related]
25. Assessment of potential thrombogenicity of coagulation factor IX concentrates in an in vitro model of human thrombogenesis.
Galan AM; Reverter JC; Bozzo J; Hernandez MR; Escolar G; Aznar-Salatti J
Thromb Res; 1999 Dec; 96(5):383-9. PubMed ID: 10605953
[TBL] [Abstract][Full Text] [Related]
26. Assessment of thrombogenicity of prothrombin complex concentrates in a porcine model.
Harrison J; Abildgaard C; Lazerson J; Culbertson R; Anderson G
Thromb Res; 1985 Apr; 38(2):173-88. PubMed ID: 4002204
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal antibody-purified factor IX--comparative thrombogenicity to prothrombin complex concentrate.
Kim HC; Matts L; Eisele J; Czachur M; Saidi P
Semin Hematol; 1991 Jul; 28(3 Suppl 6):15-9. PubMed ID: 1780766
[No Abstract] [Full Text] [Related]
28. Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate.
Hampton KK; Preston FE; Lowe GD; Walker ID; Sampson B
Br J Haematol; 1993 Jun; 84(2):279-84. PubMed ID: 8398831
[TBL] [Abstract][Full Text] [Related]
29. High sensitivity detection of activated factor IX: application to the analysis of different therapeutical factor IX concentrates and prothrombin complexes.
Kusch M; Seitz R; König H
Thromb Haemost; 1998 Apr; 79(4):778-83. PubMed ID: 9569192
[TBL] [Abstract][Full Text] [Related]
30. Use of factor VII-deficient beagles bred by artificial insemination to evaluate mechanisms of thrombosis associated with prothrombin complex concentrates.
Ferguson JM; MacGregor IR; McLaughlin LF; Prowse CV
Blood Coagul Fibrinolysis; 1991 Dec; 2(6):731-4. PubMed ID: 1799659
[TBL] [Abstract][Full Text] [Related]
31. [Thrombogenicity of a new prothrombin complex concentrate].
Klöcking HP; Klessen C; Jablonowski C; Meerbach W; Dornheim G
Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(5):645-61. PubMed ID: 6083940
[TBL] [Abstract][Full Text] [Related]
32. In vitro thrombogenicity tests of factor IX concentrates. II: effects of phospholipids and heparin.
Prowse CV; Boffa MC; Guthrie C; Pepper DS
Thromb Haemost; 1980 Feb; 42(5):1368-77. PubMed ID: 7368144
[TBL] [Abstract][Full Text] [Related]
33. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group.
White GC; Shapiro AD; Kurczynski EM; Kim HC; Bergman GE
Thromb Haemost; 1995 May; 73(5):779-84. PubMed ID: 7482403
[TBL] [Abstract][Full Text] [Related]
34. Toxicity of factor IX concentrates in mice.
Magner A; Aronson D
Dev Biol Stand; 1979; 44():185-8. PubMed ID: 544292
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
[TBL] [Abstract][Full Text] [Related]
36. [Significance of fibrinopeptide A as an indicator for coagulative analysis in thrombotic diseases].
Murakoshi T
Hokkaido Igaku Zasshi; 1982 May; 57(3):351-63. PubMed ID: 6957368
[TBL] [Abstract][Full Text] [Related]
37. A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate.
Thomas DP; Hampton KK; Dasani H; Lee CA; Giangrande PL; Harman C; Lee ML; Preston FE
Br J Haematol; 1994 Aug; 87(4):782-8. PubMed ID: 7986719
[TBL] [Abstract][Full Text] [Related]
38. Studies on the thrombogenicity of Scottish factor IX concentrates in dogs.
Cash JD; Dalton RG; Middleton S; Smith JK
Thromb Diath Haemorrh; 1975 Jun; 33(3):632-9. PubMed ID: 1154318
[No Abstract] [Full Text] [Related]
39. Post-transfusion hepatits following the use of prothrombin complex concentrates.
Roberts HR; Blatt PM
Thromb Diath Haemorrh; 1975 Jun; 33(3):610-6. PubMed ID: 1154316
[No Abstract] [Full Text] [Related]
40. Testing for potential thrombogenicity of prothrombin complex concentrates.
Snape TJ
Dev Biol Stand; 1979; 44():199-204. PubMed ID: 544295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
